Experimental group8:the maximum tolerated dose (MTD) determined by the dose escalating phase of the trial, or the dose recommended by the phase II clinical trial
Sponsors
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, West China Hospital of Sichuan University
Conditions
Acute B lymphoblastic leukemiamalignant solid tumor
Phase 1
A-319 (a bispecific T cell engager) In Refractory/Relapse B-cell Acute Lymphoblastic Leukemia: a multicenter, open-label and dose-escalating phase I trial
RecruitingChiCTR2100054600
Start: 2021-12-06Updated: 2022-11-28
Study on the Open, Dose Increasing, and Dose Expansion of A-337 in the Treatment of Malignant Solid Tumors
RecruitingChiCTR2300076545
Start: 2023-11-01Updated: 2024-05-13